Overactive bladder (OAB) affects approximately 17 million to 20 million people in the United States, yet few realize that it is a treatable condition. Many people believe that it is a natural part of the aging process and are embarrassed to discuss it. It is estimated that costs related to OAB were nearly $14 billion in this country in 2000, similar to that of gynecological and breast cancers, osteoporosis, or arthritis.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.